FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

New direction for Alzheimer's research?

Pharmawire examines the likely impact that the failure of the late-stage trial for Flurizan will have on R&D projects in the Alzheimer's arena. Experts say that the research could now head in a new direction. Article

More stories about Flurizan   Alzheimer's  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 15 + 12?
To combat spam, please solve the math question above.